NPS Pharmaceuticals, Inc. (NPSP) to Present Data from Natpara™ REPLACE Study and PARADOX Study at ENDO 2013, the Endocrine Society’s 95th Annual Meeting
6/5/2013 7:02:23 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NPS Pharmaceuticals, Inc., a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today reported that two abstracts related to the Phase 3 REPLACE study of Natpara™ in hypoparathyroidism and one abstract related to PARADOX, a 374-patient epidemiology study that assessed the clinical, social, and economic implications of hypoparathyroidism will be presented at ENDO 2013, The Endocrine Society’s 95th Annual Meeting in San Francisco, June 15-18, 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by